Novavax shares surge 20.01% intraday after securing $530M licensing deal with Pfizer for Matrix-M adjuvant.

Novavax surged 20.01% intraday after announcing a $530 million licensing agreement with Pfizer for its Matrix-M adjuvant technology. The deal includes a $30 million upfront payment, potential $500 million in development and sales milestones, and tiered royalties, positioning Matrix-M as a core growth driver. The partnership, coupled with Novavax’s existing collaborations (e.g., Sanofi, Takeda) and late-stage vaccine pipeline, signaled strong validation of its platform. CEO John Jacobs emphasized the strategic importance of Matrix-M, reinforcing investor confidence in the company’s future prospects. The immediate intraday rally reflects market enthusiasm for the deal’s revenue potential and Novavax’s expanding role in the vaccine sector.